LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Coherus Biosciences Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

0.82 2.5

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.78

Max

0.83

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-5.9M

-57M

Pardavimai

-47M

7.6M

P/E

Sektoriaus vid.

1.741

51.198

Pelnas, tenkantis vienai akcijai

-0.35

Pelno marža

-744.427

Darbuotojai

221

EBITDA

115K

-44M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+527.5% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-28M

90M

Ankstesnė atidarymo kaina

-1.68

Ankstesnė uždarymo kaina

0.82

Naujienos nuotaikos

By Acuity

50%

50%

166 / 380 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Coherus Biosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-06 14:31; UTC

Uždarbis

New York State Retirement Fund Posts 5.84% Annual Investment Return

2025-06-06 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-06 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-06 20:33; UTC

Uždarbis

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 19:36; UTC

Rinkos pokalbiai

Oil Futures Post Solid Weekly Gains -- Market Talk

2025-06-06 19:28; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

2025-06-06 18:46; UTC

Rinkos pokalbiai

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

2025-06-06 18:02; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Continues to Decline -- Market Talk

2025-06-06 16:35; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 16:34; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 16:21; UTC

Rinkos pokalbiai

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-06-06 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-06-06 16:07; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-06-06 16:07; UTC

Rinkos pokalbiai

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

2025-06-06 15:53; UTC

Rinkos pokalbiai

Mexican Inflation Seen Rising in May -- Market Talk

2025-06-06 15:36; UTC

Rinkos pokalbiai

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

2025-06-06 15:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-06 15:33; UTC

Rinkos pokalbiai

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

2025-06-06 15:16; UTC

Rinkos pokalbiai

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

2025-06-06 15:05; UTC

Rinkos pokalbiai

Silver at its Highest In Nearly 15 Years -- Market Talk

2025-06-06 14:35; UTC

Rinkos pokalbiai

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

2025-06-06 14:15; UTC

Rinkos pokalbiai

Oil Rises on U.S.-China Talks Optimism -- Market Talk

2025-06-06 14:12; UTC

Uždarbis

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

2025-06-06 14:09; UTC

Uždarbis

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Coherus Biosciences Inc Prognozė

Kainos tikslas

By TipRanks

527.5% į viršų

12 mėnesių prognozė

Vidutinis 5.02 USD  527.5%

Aukščiausias 7 USD

Žemiausias 1.05 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Coherus Biosciences Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

6 ratings

4

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.9209 / 1.05Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

166 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.